Drug Profile


Alternative Names: IONIS-APO(a)Rx; IONIS-APOA Rx; ISIS-494372; ISIS-APO(a)RX; ISIS-APOA Rx

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Apolipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperlipoproteinaemias

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Dec 2015 Discontinued - Phase-II for Hyperlipoproteinaemia in Canada, Denmark, Germany, Netherlands, United Kingdom (SC)
  • 08 Nov 2015 Efficacy and adverse event data from a phase II trial in Hyperlipoproteinaemia presented at the American Heart Association Scientific Sessions (AHA-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top